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Abstract
Extracellular RNAs (exRNAs) in biofluids have attracted great interest as potential biomarkers. 
Whereas extracellular microRNAs in blood plasma are extensively characterized, extracellular 
messenger RNAs (mRNA) and long non-coding RNAs (lncRNA) are less well-studied. We report 
that plasma contains fragmented mRNAs and lncRNAs that are missed by standard small RNA-
seq protocols due to lack of 5’ phosphate or presence of 3’ phosphate. These fragments were 
revealed using a modified protocol (“phospho-RNA-seq”) incorporating RNA treatment with T4-
polynucleotide kinase, which we compared with standard small RNA-seq for sequencing 
synthetic RNAs with varied 5’ and 3’ ends, as well as human plasma exRNA. Analyzing 
phospho-RNA-seq data using a custom, high-stringency bioinformatic pipeline, we identified 
mRNA/lncRNA transcriptome fingerprints in plasma, including tissue-specific gene sets. In a 
longitudinal study of hematopoietic stem cell transplant patients, bone marrow- and liver-
enriched exRNA genes tracked with bone marrow recovery and liver injury, respectively, 
providing proof-of-concept validation as a biomarker approach. By enabling access to an 
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unexplored realm of mRNA and lncRNA fragments, phospho-RNA-seq opens up new 
possibilities for plasma transcriptomic biomarker development.
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Introduction 
   In recent years, the discovery of a variety of extracellular RNA (exRNA) molecules present in 
the human bloodstream and other biofluids has been of great interest given their potential value 
as minimally-invasive biomarkers for a wide range of diseases (Freedman et al, 2016; Max et al, 
2018; Godoy et al, 2018; Yuan et al, 2016). To date, characterization of exRNAs in blood has 
mostly focused on microRNAs, which have been shown to be exceptionally stable in plasma 
(i.e., the acellular portion of blood) by virtue of being protected in complexes with Argonaute 
proteins and extracellular vesicles (Arroyo et al, 2011; Hunter et al, 2008). However, microRNAs 
represent a small fraction of the human transcriptome and only a small minority of microRNAs 
show exquisite tissue- or disease-specificity (Ludwig et al, 2016). The degree to which the more 
predominant components of the transcriptome, notably mRNAs and lncRNAs, are similarly 
represented in blood as exRNA is less well established. Yet mRNAs and lncRNAs are highly 
appealing from the standpoint of biomarkers for monitoring health and disease due to their 
multiple established tissue- and disease-specific gene expression signatures (Perou et al, 2000; 
Potti et al, 2006; Chen et al, 2007; Ben-Porath et al, 2008; Iyer et al, 2015; Liu et al, 2008a).
   RNA-seq has transformed transcriptome characterization in a wide range of biological 
contexts (Mortazavi et al, 2008; Wang et al, 2009) including its application to analyze exRNA in 
body fluids (Adiconis et al, 2013; Giraldez et al, 2018). These efforts have begun to elucidate the 
complex composition of exRNA in blood (Freedman et al, 2016; Max et al, 2018; Yeri et al, 
2017; Godoy et al, 2018). There have been indications of extracellular mRNA and lncRNA in 
some studies of plasma, but results have been inconsistent, with some profiling studies 
reporting a variable percentage of them and others not even reporting their presence (Freedman 
et al, 2016; Max et al, 2018; Godoy et al, 2018; Danielson et al, 2017; Koh et al, 2014; Yuan et 
al, 2016; Yeri et al, 2017; Huang et al, 2013). Moreover, these profiling studies have used a 
variety of methods to evaluate exRNA (e.g. microarrays and different methodologies for RNA-
seq) which, not surprisingly, contributes to the variation in findings across the studies.
   We hypothesized that given the high concentration of RNases in the human bloodstream 
(Kamm & Smith, 1972), mRNAs and lncRNAs, if truly present in blood plasma at all, may not 
exist in full-length form, but rather as small fragments. Furthermore, we hypothesized that 
standard ligation-based small RNA-seq methods might not detect such fragments because they 
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are designed to capture microRNAs (Hafner et al, 2008), which by virtue of being products of 
RNase III class enzymes (e.g., Dicer) consistently present 5'-monophosphate and 3'-hydroxyl 
ends (Lee et al, 2003). In contrast, the 5' and 3' ends of RNA cleavage products generated by 
other ribonucleases vary substantially, which might prevent efficient adapter ligation with typical 
small RNA-seq methods. For example, abundant RNases in human blood circulation, such as 
those belonging to the ribonuclease A superfamily (Lu et al, 2018) degrade RNA dinucleotide 
bonds, leaving a 5' hydroxyl and 3' phosphorylated product (Cuchillo et al, 2011). Therefore, we 
reasoned that in order to comprehensively sequence a broader space of exRNAs beyond 
microRNAs, it would be essential to develop modifications to small RNA-seq protocols that can 
enable capture of RNA fragments that may have these alternate 5’ and 3’ phosphorylation 
states.
   Here, we modified the standard small RNA-seq approach by incorporating both an upfront 5’ 
RNA phosphorylation / 3’ dephosphorylation step using T4 polynucleotide kinase (referred to 
here subsequently as “PNK”) and a custom, high-stringency bioinformatic data analysis pipeline 
to analyze non-microRNA small RNA fragments. This approach, which we refer to as “phospho-
RNA-seq”, revealed a large, untapped space of mRNAs and lncRNA fragments present in 
plasma. These fragments comprised tissue-specific signatures that were able to reflect 
biological processes of bone marrow reconstitution and acute liver injury in hematopoietic stem 
cell transplant (HSCT) patients. We propose that this approach opens up new opportunities for 
disease biomarker discovery through transcriptomic analysis of exRNA fragments in the 
circulation.
Results
Synthetic RNA-based technical validation of a phospho-RNA-seq protocol for recovering 
short mRNA and lncRNA fragments with ends lacking a 5’-phosphate and/or possessing 
a 3’-phosphate. 
   To evaluate the performance of both standard and phospho-RNA-seq methods for recovering 
short oligonucleotides with varying end-modifications likely to be found in human biofluids, we 
designed a synthetic reference pool comprising 476 ribonucleotides of different length (from 15 
nt to 90 nt) and sequence (Table EV1). More specifically, our pool includes 286 human 
microRNAs, 8 plant microRNAs, 164 fragments of mRNA and lncRNAs ranging from 15 nt to 90 
nt and including different end modifications (i.e. 5’ phosphorylation, 3’ phosphorylation and none 
modifications) and 18 artificial microRNA sequences as control. As depicted in Figure 1A, we 
prepared small-RNA libraries using this pool as input and following two different strategies: (i) 
standard ligation-based methodology (i.e. TruSeq small RNA protocol) and (ii) our modified 
phospho-RNA-seq approach (i.e. RNA pretreatment with PNK which phosphorylates 5’ hydroxyl 
This article is protected by copyright. All rights reserved
groups and removes 3’ phosphoryl groups from oligonucleotides, followed by standard small 
RNA library preparation methodology). Libraries were multiplexed, sequenced on a NextSeq 
platform and analyzed as described in Methods. 
   As shown in Figure 1B, both strategies were able to recover the majority of sequences with 5’ 
phosphorylation and 3’ OH in our pool, most of which are human microRNAs. In contrast, the 
phospho-RNA-seq approach recovered sequences that either lacked 5’ phosphorylation or had 
3’ phosphorylation , which were largely undetectable by the standard methodology (Figures 1B 
- 1D). We confirmed that these results were not due to differences in sequencing depth, as the 
untreated library generated 4.1 million aligned reads, compared with only 2.9 million in the PNK-
treated library. These results confirmed that standard ligation-based small-RNA protocols are 
poorly suited for capturing non-microRNA species lacking 5’ phosphorylation and, especially, 
those presenting a 3’ phosphorylation. 
Phospho-RNA-seq combined with a high stringency bioinformatic pipeline enables 
reliable detection of mRNA/lncRNA fragments in human plasma.
After validating the efficiency of our phospho-RNA-seq strategy for capturing mRNA and 
lncRNA fragments with a variety of end modifications in a setting where the ground truth is 
known (i.e. a synthetic pool of RNA), we aimed to design and test a pipeline that could enable 
reliable evaluation of mRNA and lncRNA fragments in real plasma samples, where the exRNA 
composition is unknown and the risk of false positive calling is higher. To this end, we obtained 
platelet-poor plasma from five healthy control individuals (demographic features are shown in 
Appendix Table S1), prepared triplicate libraries for each individual using both standard small 
RNA-seq methodology (TruSeq kit) and phospho-RNA-seq and performed multiplexed 
sequencing on a HiSeq platform (Figure 2A).
Initial attempts to characterize mRNA and lncRNA fragments directly from adapter-trimmed 
and length-filtered reads revealed that non-mRNA/lncRNA sequences, including fragments from 
various endogenous non-coding RNAs (defined here as rRNAs, tRNAs, microRNAs, and other 
non-coding RNAs but excluding lncRNAs, as derived from Gencode and described in detail in 
Methods) and repetitive elements, were leading to false positive detection and over-estimation 
of mRNA and lncRNA fragment abundances. To uncover relevant biological signal derived from 
mRNAs and lncRNAs, we developed a custom pipeline (Figure 2B) that employs multiple 
distinct filtering steps aimed at quantifying and removing potential sources of false signal, to 
enable the reliable detection of short mRNA and lncRNA fragments. Stage 1 of the pipeline 
involves trimming adapters, removing low-quality bases, and eliminating reads shorter than 15 
nucleotides (see Materials and Methods for additional criteria). Next, we adapted the 
sRNAnalyzer pipeline(Wu et al, 2017) to quantify and remove reads aligning to any one of 
several sequence libraries containing exogenous RNAs (bacterial, fungal and viral), various 
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endogenous non-coding RNA sequences, and other possible contaminants (transposons, 
repetitive elements and Univec contaminants) (Stage 2). Reads with no valid alignments to 
these sequence libraries in Stage 2 are then aligned to the human genome. In Stage 3, genomic 
read alignments are filtered if found to have any overlap with RepeatMasker (UCSC) and 
various endogenous non-coding annotation coordinates. This additional coordinate-based 
filtering step catches reads that were missed by the sRNAnalyzer workflow (see Materials and 
Methods for additional details).
As shown in Figure 2C, without any filtering of non-coding RNA and repeat-mapping reads, 
thousands of mRNA and lncRNA genes were falsely detected, or detected at artificially high 
levels due to a preponderance of reads aligning to transcript-embedded fragments from various 
endogenous non-coding RNA or repetitive element sequences. The alignment to sequence 
databases in Stage 2 and the coordinate-based filtering in Stage 3 provided a step-wise removal 
of false positives from these endogenous sources (Figure 2C). Accordingly, the percentage of 
reads uniquely mapped to mRNA and lncRNA exons also increases through the sequential 
filtering stages of our pipeline (Figure 2D). Therefore, our analysis demonstrates the importance 
of stringent filtering of repetitive sequences and certain non-coding RNA sequences, as failure 
to do so resulted in false-positive detection of many mRNA/lncRNA transcripts. It is also worth 
noting that sequences from libraries prepared with phospho-RNA-seq mapped more frequently 
to mRNA and lncRNA exons, than those prepared using standard small RNA-seq, with the 
former showing a 10-fold increase of mRNA/lncRNA exonic reads on average (Figure 2E).
Standard ligation based small RNA-seq pipelines are prone to false positive calling of 
mRNA/lncRNA fragments in human plasma.
To evaluate how reliable standard small RNA-seq pipelines are for calling short mRNA and 
lncRNA fragments, we processed the plasma exRNA sequencing data from a healthy individual 
through exceRpt, a pipeline specifically designed for the analysis of exRNA small RNA-seq data 
that uses its own alignment and quantification engine to map and quantify a range of RNAs 
including mRNA and lncRNA (see Materials and Methods). We then selected the 50 most 
abundant mRNA transcripts called by the exceRpt pipeline for evaluation through each stage of 
our custom high-stringency pipeline. As in our own pipeline, exceRpt first aligns adapter-
trimmed reads to several small RNA databases for quantification, and only reads with no valid 
small RNA alignments are subsequently aligned to the human genome and used for mRNA and 
lncRNA quantification. However, tracking the reads corresponding to the top 50 most abundant 
exceRpt mRNA transcripts through our own high-stringency pipeline (Figure 3A) showed that 
although all 50 transcripts were detectable at Stage 1, most of them were filtered out or 
significantly reduced in relative expression, by subsequent filtering steps in Stages 2 and 3. We 
confirmed that a high proportion of them corresponded to fragments from various endogenous 
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non-coding RNA species or repeat-mapping reads that were, therefore, ultimately filtered out in 
our pipeline (Figure 3B). Interestingly, for the libraries prepared using phospho-RNA-seq, only 
10 of the top 50 exceRpt transcripts were filtered out when analyzed through our highly stringent 
pipeline, as compared to 35 with standard small RNA-seq. These results demonstrate that 
standard small RNA-seq pipelines, even thoughtfully-designed ones like the exceRpt pipeline, 
which seek to map and remove some small RNA and repetitive sequence species prior to 
human genome alignment, are prone to false positive calling of mRNA and lncRNA fragments, 
thus limiting reliable identification of these exRNA species in plasma samples.
Assessment of short mRNA/lncRNA fragments in human plasma using phospho-RNA-seq 
and our custom, high-stringency bioinformatic pipeline.
After having validated that phospho-RNA-seq combined with a custom, high-stringency 
bioinformatic pipeline enables reliable identification of short mRNA and lncRNA fragments in 
plasma samples, we sought to assess the abundance and features of these exRNA species in 
human plasma. In order to further substantiate the validity of these cell-free mRNA fragments, 
we assessed the relative enrichment of reads aligning in the sense versus antisense orientation. 
The ligation-based library preparation we used ensures that that majority of reads are "stranded" 
-- that is, they should align in the same orientation as the transcript of origin. Spurious 
alignments from exogenous RNAs, repetitive sequences, DNA contaminants  or other noise 
introduced by sequencing artifacts is expected to be distributed more randomly, and would 
result in a more equal distribution of sense/antisense alignments. Thus, as a quality check, we 
confirmed that the exonic alignments of our plasma exRNA sequence reads were enriched for 
the sense orientation, relative to antisense, for mRNAs and lncRNAs (Figure 4A). The degree of 
enrichment for the sense orientation of lncRNAs was lower than for mRNAs, but this may be 
because the lncRNA database we used includes a diversity of lncRNA types (see Materials and 
Methods), including those overlapping mRNA transcripts on the opposite strand. Sense strand 
preference was less evident for reads aligning to introns or promoter regions of mRNA or 
lncRNA genes, consistent with the expectation that extracellular mRNA and lncRNA fragments 
result from fragmentation of mature, processed transcripts (Figure 4A). We, therefore, focused 
our analysis of plasma exRNA on reads aligning to exons of mRNA and lncRNA genes. 
We found that our strategy is able to uncover thousands of mRNAs and lncRNAs present in 
physiological conditions in plasma from healthy individuals (N=5 healthy controls) (Table EV2). 
We evaluated the read distribution of the mRNA and lncRNA fragments identified in human 
plasma with our approach (Figure 4B) and found that on average they are fairly short (i.e. 20-25 
nt range predominantly). However, it is worth mentioning that when we focused our analysis on 
the top 100 expressed mRNA and lncRNAs or on those mRNA and lncRNA expressed in all the 
samples, they tended to be slightly longer than the overall population of mRNA/lncRNA 
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fragments, suggesting that longer read lengths are more frequently associated with more 
abundant and consistently-detected genes (Figure 4B, 4D).
Among the mRNA and lncRNA fragments we found in healthy individuals were these: (i) red 
blood cell-derived transcripts including several types of hemoglobin transcripts (e.g. HBA1, 
HBA2 and HBB); (ii) platelet-derived transcripts such as platelet-derived growth factors (e.g. 
PPBP); (iii) ubiquitous, highly expressed transcripts such as ferritin chains (i.e. FTH1 and FTL), 
mitoferrin-1 (i.e. SLC25A37), conventional non-muscle myosin (i.e. MYH9), multiple 
mitochondrial transcripts (e.g. MT-TL2, MT-ND1,MT-TM, MT-TD) and actin transcripts (e.g. 
ACTB and ACTG1) and; (iv) immune-related transcripts such as MHC class I molecules (e.g. 
B2M), interleukins (e.g. IL-6) and myosin IF (MYO1F), and (v) the lncRNAs MALAT-1 and 
NEAT1 (Figure 4C and Table EV2). As expected, the mRNA and lncRNA fragments that were 
the most consistently detected across multiple individuals were also the most highly abundant 
ones (Figure 4D). 
Assessment of extracellular microRNA capture from plasma by phospho-RNA-seq.
After having demonstrated that phospho-RNA-seq combined with a stringent pipeline is 
critical for recovering mRNA and lncRNA fragments in plasma, we examined the efficiency of  
this strategy for capturing microRNAs from plasma by analyzing mature microRNA read counts 
from healthy donor plasma samples prepared with and without PNK treatment. The microRNA 
counts were obtained from the sRNAnalyzer alignment stage used in our exRNA processing 
pipeline. We found that while microRNAs were captured using the phospho-RNA-seq method, 
the standard small RNA-seq method yielded approximately ten times more microRNA reads 
(Fig EV1A). Although nearly 200 microRNAs were detected in PNK-treated samples from all five 
individuals, the additional coverage achieved by the standard small-RNA seq method enabled 
detection of 98 additional microRNAs, where detection was defined as observing them in all five 
individuals (Fig EV1B). We confirmed that these results were not due to differences in 
sequencing depth, as the standard small-RNA-seq libraries were sequenced to lesser depth 
(median of 9.2 million reads per individual after adapter trimming and size filtering) than the 
phospho-RNA-seq libraries (median of 27.9 million reads).
We found that 21 of these additional microRNAs were seen exclusively using standard small 
RNA-seq (i.e., they had zero reads across all five individuals with phospho-RNA-seq) (Fig 
EV1C). Interestingly, we found some microRNAs that were exclusively captured with phospho-
RNA-seq, in spite of the lower read coverage for microRNAs with this method (Fig EV1D). 
Closer inspection revealed that 16 of the 30 PNK-specific microRNAs were likely fragments of 
transposable or repetitive elements, or were non-functional, mis-annotated microRNAs now 
removed from miRBase annotations. However, excluding these artifactual microRNAs, 14 bona 
fide microRNAs were detected specifically in PNK-treated samples, indicating that a small 
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subset of microRNAs may be present in a modified form in plasma that prevents capture with 
traditional methods. Overall, however, our analysis indicates that standard methods are 
preferable over phospho-RNA-seq when the goal is to exclusively characterize microRNA 
profiles in plasma. 
Pathophysiologic processes are reflected in plasma exRNA transcriptome profiles 
revealed by phospho-RNA-seq. 
   Having confirmed that the phospho-RNA-seq approach with high-stringency bioinformatic 
analysis enables the detection of mRNA and lncRNA fragments consistently expressed in 
plasma from healthy individuals under homeostatic conditions, we sought to evaluate if dynamic 
(patho)physiological processes would be reflected in the expression patterns of mRNA and 
lncRNA extracellular fragments. To this end, we collected serial plasma samples from patients 
undergoing allogeneic HSCT (N=26 samples from 2 different patients), prepared phospho-RNA-
seq libraries from each time point and performed multiplex sequencing using a HiSeq platform 
(Figure 5A). 
We reasoned that in order for mRNA/lncRNA exRNA sequences in plasma to have potential 
as biomarkers, we should see patterns in specific sets of genes that correlate over time to 
biological processes happening within the patients. We began our analysis by using the EBSeq-
HMM R package (Leng et al, 2015), which uses an autoregressive Hidden Markov modeling 
strategy to test for genes that show evidence of differential expression over time (Leng et al, 
2015).  This analysis resulted in 690 (patient P04) and 275 (patient P07) genes showing 
significant (FDR < 0.01) evidence of dynamic changes in expression (Tables EV3 and EV4). 
We hypothesized that differentially-expressed transcripts with similar expression patterns might 
have similar tissue origins or biological functions. Using an unsupervised clustering strategy 
from the R package, WGCNA, we identified sets of the differentially expressed genes showing 
concordant temporal coexpression patterns (Tables EV3 and EV4). Among the differentially-
expressed transcripts of both patients, we found multiple transcripts known to be specific to or 
enriched in bone marrow (Fig 5B). The bone marrow transcripts clustered into distinct co-
expression sets identified by WGCNA. In fact, a hypergeometric test identified three distinct 
temporal co-expression clusters for subject P04 and two for subject P07, which were 
significantly enriched for bone marrow transcripts. Since HSCT is a process that can be followed 
through the peripheral white blood cell count (WBC), we plotted abundance of the significantly-
enriched clusters of bone marrow exRNA transcript fragments over time along with WBC count. 
As shown in Figure 5C, we saw that transcript fragments corresponding to the bone marrow 
gene set tracked generally with the dynamics of bone marrow reconstitution, initially declining as 
expected during the period of early neutropenia in the first week after transplant followed by a 
rise corresponding to recovery of the WBC count. 
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Interestingly, co-expression clusters were enriched for genes specific to or enriched in other 
somatic tissues. In fact, the most significantly overrepresented tissue in both individuals was the 
liver, with nearly all liver-enriched genes grouped in the same co-expression cluster (Fig 6A and 
6B). We wondered whether the liver-enriched transcripts corresponding to our liver gene set 
would track temporally with liver injury, which is common in HSCT patients, sometimes as a side 
effect of medications given as part of their clinical care. By plotting blood levels of serum 
aminotransferases (AST and ALT), two enzymes produced by liver cells that are used clinically 
for detecting liver injury, together with levels of exRNA liver-enriched transcript fragments over 
time, we saw that levels of the liver-enriched RNA fragments showed dynamic changes and 
followed a similar trend as the pattern of changes in AST/ALT (Figure 6C and 6D). Thus, we 
concluded that bone marrow-specific and liver-specific exRNA transcript fragments show distinct 
expression patterns corresponding to known biology as measured by relevant, established 
clinical laboratory markers. These results provide a proof-of-concept that this approach can 
provide access to a circulating transcriptome with potential for biomarker development. 
Discussion
 There has been rapidly growing interest in the study of exRNAs, both for their potential 
clinical application as biomarkers of disease measurable in biofluids such as blood (Roser et al, 
2018; Schwarzenbach et al, 2011), as well as for their potential biological functions (Zhang et al, 
2010; Shah & Calin, 2014; Hu et al, 2012). Most studies of exRNAs in human biofluids to date 
have focused on microRNAs. Unlike microRNAs, which are a small fraction of total genes, 
lncRNAs and mRNAs comprise a majority of the transcriptome and hold great potential as 
biomarkers given their exquisite tissue specific expression (Iyer et al, 2015; Liu et al, 2008b) and 
the fact that mRNA gene signatures in tissues have proven to be powerful biomarkers in 
different clinical settings (Perou et al, 2000; Potti et al, 2006; Ben-Porath et al, 2008; Chen et al, 
2007) . Thus, the ability to read transcriptomic information through exRNA profiles in blood 
plasma is important for enabling for clinical applications.
 However, mRNAs and lncRNAs have not been easily or consistently detectable as exRNA in 
blood plasma. RNAs found in plasma have generally been seen to be fragmented relative to 
their cellular RNA counterparts (Mitchell et al, 2008), and most studies have used small RNA-
seq protocols that are designed to sequence microRNAs. These protocols typically employ RNA 
ligase-based adapter ligations, followed by reverse transcription and PCR to generate libraries 
for high throughput sequencing. Such protocols commonly rely on the presence of 5’-phosphate 
and 3’-hydroxyl ends on the target RNA (Hafner et al, 2008), which are produced by the RNase 
III class of ribonucleases, including the double-stranded ribonuclease Dicer that is responsible 
for processing precursor microRNAs to generate mature microRNAs (Knight & Bass, 2001; Ha & 
Kim, 2014). We hypothesized that mRNA and lncRNA transcripts in the blood circulation are 
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likely to be acted upon by different classes of ribonucleases that may not produce ends 
conducive to sequencing by standard small RNA-seq library protocols. Specifically, abundant 
RNases in human circulation such as those belonging to the ribonuclease superfamily A (Lu et 
al, 2018) degrade RNA dinucleotide bonds leaving a 5' hydroxyl and 3' phosphorylated product 
(Cuchillo et al, 2011), thus rendering cleavage products unsuitable for standard ligation-based 
library preparation protocols. 
We sought to test this hypothesis using both “ground truth” samples of synthetic RNA pools 
with variable 5’ and 3’ end modification states and biological (plasma) samples. Our results 
clearly showed that PNK treatment vastly increased the recovery of fragments either lacking a 
5’-phosphate or having a 3’-phosphate. This is consistent with the properties of PNK, which has 
both 5’ kinase and 3’ phosphatase activities (Cameron & Uhlenbeck, 1977; Richardson, 1965; 
Novogrodsky & Hurwitz, 1966). Moreover, these results highlight that standard ligation-based 
small RNA-seq approaches are not well suited to characterize exRNA beyond microRNAs and 
other sequences sharing the same end chemistries. Our method revealed that human plasma 
contains abundant mRNA and lncRNA transcript fragments, corresponding to thousands of 
human genes. Thus, mRNA and lncRNA fragments are a substantial component of the 
extracellular transcriptome in human plasma. Our incorporation of synthetic RNA pools as a 
ground truth reference was especially important in our study, as it allowed us to demonstrate 
clearly that lack of 5’ phosphorylation and presence of 3’ phosphate are both impediments to 
recovery of these fragments by standard small RNA-seq. 
Although PNK treatment enabled much greater recovery of sequences lacking 5’P and/or 
3’OH, PNK is known to exhibit target nucleic acid sequence-dependent biases in its kinase and 
phosphatase activities (Lee et al, 2013). These very likely influence the distribution of 
sequences we are able to recover with the current iteration of the phospho-RNA-seq method, 
limiting the accuracy of estimating the relative abundance of different mRNA/lncRNA fragments 
within a sample. Incorporation of an Optikinase step prior to PNK has been reported to mitigate 
bias observed when using PNK alone (Lee et al, 2013), and could be tested in future iterations 
of the phospho-RNA-seq method. In addition, future studies using large, diverse sequences of 
RNA fragments with varying 5’ and 3’ phosphorylation states could be used to deeply 
characterize sequence-dependent biases of PNK treatment in the context of phospho-RNA-seq 
for recovery of mRNA/lncRNA fragments. Finally, the use of downstream library protocols that 
have less intrinsic bias (Giraldez et al, 2018) than the one used here (TruSeq) has potential to 
increase the overall recovery of unique mRNA/lncRNA fragments, as well as to improve the 
accuracy of estimating relative abundance of different fragments within a sample. 
 A key lesson learned from our study is the importance of a highly stringent data analysis for 
accurate identification of mRNA and lncRNA fragments from phospho-RNA-seq sequence data. 
This is because these relatively short sequences frequently align to multiple locations in the 
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genome. Thus, short fragments of RNAs arising from repetitive DNA transcription or ribosomal 
RNA fragments for example, can spuriously align to mRNA and lncRNA exons. To avoid these 
false positive calls, we developed a three step filtering pipeline specifically designed for the 
reliable identification of mRNA and lncRNA fragments. To date, pipelines for the analysis of 
small RNA-seq data such as the exceRpt pipeline 
(http://genboree.org/theCommons/projects/exrna-tools-may2014/wiki/Small_RNA-seq_Pipeline) 
have been designed with a predominant focus on microRNA annotation. Perhaps not 
surprisingly, we found that when applied to phospho-RNA-seq data analysis for mRNA/lncRNA 
identification, there was a high rate of false positive annotation. It is possible that this 
phenomenon may have affected prior results of plasma exRNA profiling using non-PNK-based 
approaches which although focused primarily on microRNAs, also commented on the finding of 
mRNA and lncRNA transcripts in plasma (Max et al, 2018; Yuan et al, 2016; Huang et al, 2013). 
Future work could determine the extent to which reports of mRNA and lncRNA fragments from 
libraries not incorporating PNK may reflect false positive mis-annotation, due to limitations of 
bioinformatic analysis pipelines. We propose that the high-stringency pipeline we describe here 
is one approach for mitigating the false positive rate, and there may be further bioinformatic 
approaches that can also be developed. 
We must acknowledge, however, that the strict filtering used to remove repeats, although 
effective in reducing false positives, also potentially removes some valuable information and can 
lead to false negatives. Future work could utilize additional features such as high-confidence 
alignments throughout the exons of a gene in the proper orientation relative to the transcript. 
This may provide enough evidence to enable us to capture reads aligning to embedded 
repetitive sequences in bona fide mRNA/lncRNA transcripts, for example.
PNK is a well-characterized enzyme frequently used to create appropriate and 
homogeneous RNA ends before long RNA sequencing. Specifically, this enzyme has been used 
in long RNA sequencing protocols to render tissue RNA suitable for adapter ligation after 
experimental heat- or alkali-based fragmentation (Lee et al, 2013; Lamm et al, 2011). PNK has 
also been included in protocols aimed to identify 5’PPP moieties that correspond to 
transcriptional start sites in bacteria (i.e. differential RNA-seq) (Vvedenskaya et al, 2015). In 
contrast, PNK is not generally used as part of small RNA protocols and it has not been 
specifically evaluated as an strategy for revealing novel mRNA/lncRNA fragment sequences in 
biological samples such as plasma, which are missed by standard ligation-based small RNA 
protocols. 
 We applied phospho-RNA-seq to analyze longitudinal plasma samples from HSCT patients 
for two reasons. The first was to provide additional validation for our methods and data analytic 
pipeline, in that finding gene signatures in plasma that correspond to known time-dependent 
biological changes in patients would make it highly unlikely that the mRNA/lncRNA fragments 
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we found were spurious and due to mis-annotation, for example. The second was to establish 
the proof-of-concept that mRNA/lncRNA fragment gene signatures in plasma correlate with 
human biology, indicating the potential of this method as a new, broadly applicable “liquid 
biopsy” approach. As shown here, we found through an analysis beginning with temporal 
plasma exRNA gene expression profiles and progressing to identify tissue-specific gene sets 
over-represented in the dynamic profiles, that specific gene signatures corresponding to bone 
marrow and liver both tracked in a manner that paralleled the dynamic processes of bone 
marrow reconstitution and liver toxicity, respectively.
The results in HCT patients indicate that the phospho-RNA-seq approach, when combined 
with high-stringency bioinformatic data analysis, could be applied to developing biomarkers for a 
range of diseases in which tissue injury figures prominently. For example, this could include 
evaluation of the cause of hepatic injury, where plasma liver transcript signatures might provide 
more detailed information about underlying etiology than standard liver enzyme measurements 
in blood, thus assisting with differential diagnosis. Similarly, plasma transcriptome signatures 
may inform about damage to other organs, as can occur as a result of myocardial ischemia, 
autoimmune diseases, placental dysfunctions during pregnancy, and cancer treatment (e.g., 
chemotherapy, immunotherapies). We speculate that cancer tissue-specific transcript gene sets 
could also be developed for detection and longitudinal monitoring of a variety of cancer types.
Although most prior plasma exRNA studies have focused on microRNAs, mRNAs in plasma 
have been reported using methodology other than phospho-RNA-seq. In particular, a study 
using a long RNA-seq random primer cDNA synthesis protocol detected mRNAs and lncRNAs 
in plasma (Koh et al, 2014). Given that the minimal length of RNAs generally captured by that 
protocol is larger than what we observed with phospho-RNA-seq, we expect that approach is 
unlikely to have captured many of the mRNA/lncRNA fragments found in our study. Taken 
together, the results suggest that exRNA transcripts of a broad range of lengths might coexist in 
the human circulation. It remains an open question at this point as to what fraction of the plasma 
exRNA transcriptome is present as shorter fragments of the form revealed in our study, or as 
presumably longer RNAs reported in prior work (Koh et al, 2014). The shape of the exRNA size 
distribution observed in our data would indicate that longer fragments (e.g., > 100 bases) may 
exist, but may be a minority. However this question would need to be addressed in future 
studies to obtain a more accurate characterization of the exRNA transcriptome present in blood 
and other biofluids. 
Although our phospho-RNA-seq strategy allowed us to expand the spectrum of sequences 
that can be detected in plasma (i.e. sequences lacking 5’ phosphorylation and/or presenting a 3’ 
phosphate end), there are certainly still limitations of this approach. Whereas we expect that 
most of the cleavage products derived from mRNA/lncRNA in circulation will present 5’ OH and 
3’P due to the abundance of superfamily A RNAses in plasma, it is possible that there are 
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exRNAs in plasma with end groups that are not addressed by our methodology (e.g. 5’ cap). 
Second, it is worth mentioning that the efficiency of phospho-RNA-seq for identifying 
mRNA/lncRNA fragments is affected by the recovery of other abundant plasma fragments such 
as ribosomal RNA and Y RNA that can dominate the sequencing data, thus reducing the depth 
of sequencing available for detecting mRNA and lncRNA fragments. To this end, we foresee 
that in the future, the sensitivity for detecting relevant mRNA and lncRNA fragments in plasma 
might be improved by designing specific methods for depleting abundant, undesired fragments 
such as fragments of rRNAs and Y RNAs, or for enriching for fragments corresponding to panels 
of selected transcripts. It is clear that there is still room for method improvement and there may 
be many more mRNA and lncRNA fragments in plasma than we have identified here. It is also 
worth noting that new ligation-free strategies have been recently developed for small RNA-seq 
(Turchinovich et al, 2014). Future studies will be required to determine the efficiency and 
effectiveness of these approaches for detecting mRNA and lncRNA fragments in circulation. 
Moreover, taking into account our results, we envision that sequence data analytic pipelines 
specifically designed for reliable analysis of mRNA/lncRNA fragments, such as the one 
described here, will be required for the analysis of exRNA sequencing data generated with these 
strategies. 
In addition to their potential utility as biomarkers in human disease, there also remains the 
question of whether these circulating extracellular mRNA and lncRNA fragments play any 
physiological role. Multiple intriguing but controversial studies have suggested that some 
extracellular microRNAs serve a functional role by mediating cell-cell communication (reviewed 
in (Tkach & Thery, 2016)). Another recent report showed that the noncoding RNA RN7SL1 can 
be transferred between cells via an extracellular form, resulting in activation of an innate 
immune response in the recipient cell (Nabet et al, 2017). Although it is unlikely that the mRNA 
fragments we observed retain sufficient information to direct meaningful protein coding activity, 
we speculate that there may be some specific fragments that could be functional. They might 
serve as an intercellular signal through their own RNA sequence, or perhaps through 
interactions with associated RNA binding proteins that might be bound to the fragments. 
In summary, our results highlight that there is greater complexity of the extracellular 
transcriptome in human biofluids than previously known and that phospho-small RNA-seq can 
provide access to transcriptomic signatures in plasma that are inaccessible by standard small 
RNA-seq methods. The methodology presented here provides access to a new class of 
extracellular RNAs for development as liquid biopsy biomarkers for a variety of diseases. In 
addition, it may be useful to investigate this technique for application to other settings where 
RNA is highly fragmented, including formalin-fixed paraffin-embedded archival tissue 
specimens, as well as extremely old specimens of cells or tissues, where RNA may likewise be 
present in highly fragmented form.
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Materials and Methods
Synthetic reference sample. A synthetic equimolar pool containing 476 synthetic RNA 
oligonucleotides was prepared in an RNase-free environment and working on ice to minimize 
degradation. The pool was prepared by combining (i) 286 human microRNAs (ii) a set of 190 
additional, custom-synthesized RNA oligonucleotides, to generate the pool in which each of the 
476 RNA oligonucleotides is present at equimolar concentration. The latter set of 190 RNA 
oligonucleotides comprises microRNAs and non-microRNA sequences of varied length from 15 
to 90 nt, which were synthesized, HPLC purified and quantified spectrophotometrically by IDT 
(Coralville, IA, US). The pool of RNA oligonucleotides is available to qualified investigators 
seeking to reproduce the synthetic equimolar for non-commercial purposes, by request of the 
corresponding authors (as long as supplies last). The resulting equimolar pool was aliquoted in 
prelabeled DNA-, DNase-, RNase-, and pyrogen-free screw cap tubes with low adhesion 
surface and stored immediately at −80 C. The complete list of RNA sequences comprising the 
equimolar pool is provided in Table EV1.
Biological samples. Plasma samples from 5 healthy donors and serial plasma sample from 2 
patients undergoing allogeneic HSCT were collected in 10-mL K2EDTA plasma tubes 
(Vacutainer 366643; Becton Dickinson, Franklin Lakes, NY, US) and processed within one hour 
of blood draw following a two centrifugation protocol to obtain platelet-poor plasma as previously 
described (Cheng et al, 2013): (i) 3,400 xg at room temperature for 10 minutes with high brake; 
and (ii) 1940 xg at room temperature for 10 minutes without brake. Plasma was stored at -80C 
until RNA isolation. The University of Michigan IRB approved the study protocol to consent 
participants and collect samples. Informed consent was obtained from all subjects, and the 
samples were subsequently de-identified before distributing to the laboratory personnel 
generating the libraries. The studies conformed to the principles set out in the WMA Declaration 
of Helsinki and the Department of Health and Human Services Belmont Report.
RNA was isolated from 200 ul of plasma using the miRNeasy mini kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s protocol with the following modifications. Plasma samples were 
mixed with five sample volumes of QIAzol reagent and vortexed for 10 s. Samples in QIAzol 
were incubated at room temperature for 5 min to inactivate RNases. Next 0.2 volumes of 
chloroform were added to each sample. At that point, the manufacturer’s protocol was followed.
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Library preparation and sequencing. The input for library preparation was 10 femtomoles of 
RNA for the synthetic equimolar pool and 5 μl of RNA for the biological plasma samples.
Standard ligation-based small RNA libraries were prepared using the TruSeq small RNA kit 
(Illumina, San Diego, CA, US) according to the manufacturer’s instructions. Size selection was 
performed using pre-cast 6% acrylamide gels (Invitrogen, Carlsbad, CA, US) including all 
products from 140-200 bp plus any additional visible bands of greater size. To perform phospho-
RNA-seq, synthetic and plasma RNA samples were pretreated with T4 polynucleotide kinase 
(NEB, Ipswich, MA, US) using an RNA input of 7 ul in a final reaction volume of 10 ul and 
incubated at 37 C for 30 minutes following the manufacturer’s instructions. After the enzymatic 
treatment, synthetic RNA samples were heat inactivated at 65C for 20 minutes and biological 
RNA samples were purified by performing sequential washes in silica columns (Zymo, Irvine, 
CA, US): (i) 900 ul of buffer RWT (Qiagen, Hilden, Germany); (ii) 900 ul of buffer RPE (Qiagen, 
Hilden, Germany); (iii) 900 ul of ethanol 200 proof, molecular biology grade (Fisher Scientific, 
Waltham, MA, US) and; (iv) 900 ul of 80% ethanol. Libraries were then prepared using the 
TruSeq small RNA kit according to the manufacturer’s instructions. Size selection was 
performed as described above. For the libraries generated from patients undergoing HSCT we 
narrowed the range of size selection to 140-165 bp to reduce the abundance of contaminants 
such as Y RNAs.
   Libraries were multiplexed and sequenced using the Illumina NextSeq 500 (synthetic 
equimolar pool) and Illumina HiSeq 2500 (healthy controls and patients undergoing allogeneic 
HSCT) specifying 75 bp and 50 bp single-end runs, respectively. 
Computational Methods
exRNA Processing Pipeline
TruSeq adapters and stop oligo sequences were trimmed with cutadapt (v 1.91) using 
processing steps adapted from the sRNAnalyzer workflow (Martin, 2011; Wu et al, 2017). The 
sRNAnalyzer framework was also adapted to align adapter-trimmed reads 15 nt and longer to 
several sequence databases containing known small RNA families and contaminant sequences 
(Wu et al, 2017). A table with descriptions of the included sequences databases are provided in 
Appendix Table S2. Up to two mismatches were allowed in the alignment. 
Reads that had no valid alignments to the various endogenous non-coding RNA sequences and 
contaminant databases were aligned to the human genome (GRCh38) using STAR (v 2.5.0A) 
(Dobin et al, 2013). The following parameters were altered from default:
outFilterMultimapNmax=1000000; outFilterMismatchNoverLmax= 0.1; outFilterMatchNmin=15; 
outFilterMatchNminOverLread=0.9; outMultimapperOrder=Random ; outSAMtype=BAM 
Unsorted ; outReadsUnmapped=Fastx ; outSAMattributes=All ; 
outSAMprimaryFlag=AllBestScore ; alignIntronMax= 1; alignIntronMin= 2; 
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alignSJDBoverhangMin=999
These parameters remove the splicing-aware alignment capability and limit the extent of “soft-
clipping” at the ends of the alignment.
Synthetic Pool Library Analysis
Illumina NextSeq reads from equimolar synthetic pool libraries were processed to trim 
adapters, remove low-quality bases and filter short reads using the exRNA processing pipeline 
described above. Reads as short as 15 nt were allowed for detection of the shortest oligos in the 
pool. STAR (v2.5.0A) was used to align the preprocessed reads to the equimolar pool 
sequences. The following alignment parameters were altered from default: 
outFilterMultimapNmax 1000000; outFilterMismatchNoverLmax  0.1; outFilterMatchNmin 15; 
outFilterMatchNminOverLread 0.9; outMultimapperOrder Random; outSAMtype BAM Unsorted; 
outSAMunmapped Within; outSAMattributes All; outSAMprimaryFlag AllBestScore; 
alignIntronMax  1; alignIntronMin  2; alignSJDBoverhangMin 999. Read alignments were loaded 
into R for processing and analysis. Alignments were further filtered, requiring the alignment to 
match at least 90% of the synthetic pool sequence in the sense orientation, and be at least 15 nt 
in length after soft-clipping. Read counts were scaled for multi-mapping, dividing the counts by 
the number of valid alignments obtained from the “NH” tag in the bam alignment file.
MicroRNA Analysis
Read counts for mature human microRNAs were taken from the sRNAnalyzer “.profile” 
counts generated in the processing pipeline. Only read counts with <= 1 mismatch in the sense 
orientation were used. Read counts for each microRNA were summed across technical 
replicates. Library size-adjusted read counts were calculated as counts-per-million.
MicroRNA genomic coordinates (GRCh38) were obtained from miRBase V22 
(http://www.mirbase.org/). Accession numbers missing from the coordinate gff files 
corresponded to microRNAs removed from miRBase due to lack of functional evidence, and 
were annotated as “missing from miRBase”. Transposon and repeat-associated microRNAs 
were annotated by overlapping microRNA coordinates with the RepeatMasker coordinates 
(UCSC Genome Browser; hg38), requiring a minimum of 1 nt overlap in either orientation.
Multi-mapping scaling and gene quantification.
Read counts were weighted using a strategy similar to that employed by CSEM, which 
gathers mapping information from neighboring read alignments to weight read counts towards 
loci with the most unambiguous mapping information (Chung et al, 2011). Our strategy differs in 
that we 1) gather mapping information from neighboring read alignments across all samples in 
the cohort, 2) restrict our search to directly overlapping fragments, and 3) retain the mapping 
ambiguity information to allow identification of commonly co-mapping genes. To do this, a 
bipartite network was created using the R package, igraph, to connect reads with all overlapping 
clusters of mapped loci (Csardi G, Nepusz T: The igraph software package for complex network 
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research, InterJournal, Complex Systems 1695. 2006). All connected components were 
identified, using the mapping ambiguity information from all connected reads to weight reads 
more strongly to those regions with more unambiguously-mapped reads. Read alignments were 
annotated for overlap with A) Gencode transcripts, B) Gencode various endogenous non-coding 
RNAs and C) RepeatMasker annotation coordinates (UCSC genome browser). All alignments 
were removed for any read aligning to Gencode various endogenous non-coding RNA or 
RepeatMasker loci (minimum 1 bp overlap in either orientation). 
Comparison with exceRpt pipeline
The exceRpt small exRNA analysis pipeline (v 4.6.2) implemented on the Genboree 
Workbench (http://genboree.org/java-bin/login.jsp) was used to process and analyze healthy 
control samples for a healthy control (ULMC 135), prepared both using the standard TruSeq 
small RNA library protocol, and the modified phospho-RNA-seq method. Default exceRpt 
pipeline parameters were used, except to set the minimum read length to 16, and to specify 
TruSeq small RNA adapters for trimming. Read counts from Gencode transcripts were obtained 
from the post-processed exceRpt output files, and were compared with the ULMC135 read  
counts from our pipeline collected at: (Stage 1) after adapter trimming and size filtering, (Stage 
2) after sRNAnalyzer alignment and contaminant removal and (Stage 3) after genome alignment 
and removal of RepeatMasker and various endogenous non-coding RNA coordinate-based 
annotations. Reads from each stage were aligned to the human genome with STAR, using the 
same alignment parameters described above. These parameters were largely copied from those 
used by the exceRpt pipeline to make the alignments as comparable as possible.Comparison 
was limited to genes detected by both pipelines. Because the exceRpt pipeline output included 
only summarized gene abundance, the percent of various endogenous non-coding RNA or 
repeat-aligned reads were based on the alignments from our pipeline. An alignment was 
considered “sRNA or Repeat-Aligned” if any alignments for that read overlapped RepeatMasker 
or Gencode various endogenous non-coding RNA coordinates (minimum 1 nt overlap on either 
strand). Fragments were summarized at the gene level using muti-mapping-weighted exon-
aligned fragments, comparable to that used by the exceRpt pipeline for gene-level 
quantification.
Cell free RNA enrichment in coding and non-coding regions of mRNA and lncRNA 
transcripts
Exon, intron and promoter ( 2 kb upstream + 0.2 kb downstream nt) coordinates were 
extracted from Gencode (v27) protein-coding and long non-coding RNA annotations. 
RepeatMasker and sRNA-filtered genomic alignments from the five healthy individuals were 
intersected with these coordinates, requiring a minimum of 1 bp of overlap in either orientation. 
Ambiguous annotations were allowed, but counted only once per unique combination of read 
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and feature. Read alignments were considered “Sense” or “Antisense” based on the relative 
orientation of the read alignment and the mRNA or lncRNA feature. Read length distributions 
and gene abundance was calculated based on sense-aligned exonic reads.
Analysis of Hematopoietic Stem Cell Transplantation Cohort
HiSeq reads from P04 and P07 HSCT patients were processed and filtered as described 
above. Gene-level counts were calculated separately for P07 and P04 samples, using the multi-
mapping-weighted read counts from mRNA and lncRNA exon-aligned read fragments.The 
resulting gene count matrices were normalized across samples using a robust Geometric Mean 
of Pairwise Ratios (GMPR) method, suitable for sparse data sets (Chen et al, 2018). The 
GPMR-calculated size factors were provided as input to the R package, EBSeq-HMM, which 
employs an autoregressive Hidden Markov Modeling strategy to identify genes with non-static 
expression dynamics over the course of the time series (Leng et al, 2015). EBSeq-HMM was 
run separately for P04 and P07 samples. An initial run was performed using a low number of 
iterations (n=5) to test a range of fold-change estimates (1.0 to 2.0, by 0.2). The estimate that 
maximizes the log likelihood was then used for a second run of the algorithm with a higher 
number of iterations (100). Significantly altered genes were selected at an FDR cutoff of 0.01 
(Leng et al, 2015). GMPR-normalized read counts from the significantly-altered genes were 
clustered using the WGCNA workflow (Langfelder & Horvath, 2008) 
Tissue Enrichment
Databases of tissue-enriched genes were obtained from GTex and Human Protein Atlas 
data curated by the TissueEnrich R package (Jain & Tuteja, 2018). Significant enrichment was 
determined with a hypergeometric test, and using a background of all genes used as input to 
EBSeq-HMM analysis (Leng et al, 2015). 
Data and code availability.
Sequencing data reported here are available at GEO, under the superseries, GSE126051. R 
code and processed data files are available on GitHub 
(https://github.com/rspengle/phosphosRNAseq_Manuscript_Analysis). 
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Figure Legends
Figure 1. A modified protocol overcomes the low efficiency of standard ligation-based small 
RNA library preparation methods for cloning short RNA sequences lacking 5’ phosphorylation or 
possessing 3’ phosphorylation. 
A) Schema of experimental design. 
B) Boxplots summarize the mean count per million (CPM) observed for sequences contained in 
the synthetic equimolar pool sequences (y-axis, log10 scaled) presenting different end 
modifications (x-axis), as measured from libraries prepared using a standard ligation based 
small-RNA protocol (PNK (-)) and the phospho-RNA-seq strategy (PNK (+)). Boxes represent 
the mean +/- interquartile range (IQR), and whiskers represent 1st/3rd quartile 1.5 * IQR. 
Boxplots summarize mean CPM values for n = 352 (5’ phosphorylated + 3’ OH sequences), n= 
60 (5’ OH + 3’ OH sequences ) and n = 60 (5’ OH + 3’ phosphorylated sequences). Significant 
bonferroni-adjusted p-values are shown from one-tailed Wilcoxon Rank Sum tests for 
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differences in abundance between PNK (+) and PNK (-), for sequences with the end chemistries 
shown (alternative hypothesis PNK + > PNK -). 
C, D) Scatter plots showing the read distribution (CPM) observed for sequences of the synthetic 
equimolar pool with 5’ phosphorylation (red dots) and (C) without end modifications (teal dots) or 
(D) with 3’ phosphorylation (teal dots) as measured from libraries prepared using a standard 
ligation-based small-RNA protocol (x-axis) and the phospho-RNA-seq strategy (y-axis). Marginal 
density plots are included as a summary of the data. 
Figure 2. Phospho-RNA-seq combined with stringent contaminant sequence filtering reduces 
false positive mRNA/lncRNA fragments. 
A) Schema of experimental design. 
B) Schema of bioinformatic analysis pipeline. 
C) Scatter plot showing the percentage of reads aligned to repeats and small RNAs (x-axis) for 
the each filtering stage of our custom pipeline. Dots represent the mean CPM calculated for 
each gene across the five healthy control individuals. 
D) Boxplots show the fraction of genome alignments that are unambiguously-aligned to mRNA 
and lncRNA exons, shown as the percent total reads aligned at each filtering stage. The points 
represent and the boxplots summarize the percentages calculated from combining alignments 
from three technical replicates for each of the (n = 5) healthy individuals. Boxes represent the 
mean +/- IQR, and whiskers represent 1st/3rd quartile 1.5 * IQR. 
E) Barplots show the number of uniquely-mapped (teal) and multi-mapped (red) mRNA and 
lncRNA exonic reads remaining after the final filtering stage (Stage 3). Counts are plotted for 
each of the five healthy control individuals (x-axis) both in untreated (left panel) and PNK treated 
(right panel) samples. The count values are shown along with the corresponding bar plots.
Figure 3. Re-evaluation of top transcripts called by a standard small RNA-seq analysis pipeline 
using our custom high stringency analysis pipeline. 
A) The exceRpt exRNA-seq pipeline was used to analyze  plasma RNA from a healthy control 
(ULMC135) and the 50 most highly-expressed protein-coding mRNAs were quantified using our 
pipeline. Boxplots summarize the read counts measured when processed through our repeat 
filtering stages. Results from both PNK treated and untreated samples (x-axis) are shown. Gene 
abundances are shown as log10 read counts + 1 (y-axis). Individual points are color-coded by 
the rank of the gene expression observed at the stage indicated (rank 1 = highest expressed). 
Boxes represent the mean +/- IQR, and whiskers represent 1st/3rd quartile 1.5 * IQR. 
Bonferroni-adjusted p-values are shown from Wilcoxon Rank-Sum tests comparing the gene 
expression ranks in filtering stage 1 versus stage 2 or stage 3. 
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B) Scatterplot shows the CPM values reported by the exceRpt pipeline for the 50 most highly 
expressed mRNA or lncRNA genes (x-axis), versus the percentage that we found to overlap 
RepeatMasker or sRNA annotations (y-axis). Values are plotted for ULMC135  + PNK (teal) and 
- PNK (red). 
Figure 4. Assessment of short extracellular mRNA/lncRNA fragments in human plasma using 
optimized library preparation and analysis methods. 
A) Boxplots showing the percentage of unambiguously annotated reads (y-axis) for mRNA and 
lncRNA exons, intron and promoters located in the sense and antisense strand as measured by 
phospho-RNA-seq in plasma samples from healthy controls (N=5). Boxes represent the mean 
+/- interquartile range (IQR), and whiskers represent 1st/3rd quartile 1.5 * IQR. 
B) Read length distribution of exon-aligned reads in plasma samples from healthy controls (N=5) 
prepared with phospho-RNA-seq. Read length is shown on the x-axis and the percent of exon-
aligned reads shown on the y-axis. Dots represent percentages calculated for each of the five 
healthy control individuals. A smoothed trend line is shown and color coded based on the 
categories indicated. 
C) Boxplots summarize the read length (x-axis) distributions for the 50 most highly-abundant 
genes (y-axis) across the five healthy control samples. Genes are sorted by median read length. 
Boxes represent the mean +/- interquartile range (IQR), and whiskers represent 1st/3rd quartile 
1.5 * IQR.
D) Violin plots showing gene abundance expressed as mean read counts (y-axis) as a function 
of the number of participants where they were detected (x-axis). 
Figure 5. Relationship between temporal patterns of dynamically co-expressed plasma 
mRNA/lncRNA fragments and bone marrow recovery in patients undergoing allogeneic HSCT. 
A) Schema depicts timing of the serial sample collection, experimental methodology and 
bioinformatics and enrichment analysis. 
B) Heatmaps show the expression patterns of bone marrow-enriched genes that were detected 
in patients P04 (left) and P07 (right) datasets, and found differentially abundant by EBSeq-HMM 
(FDR < 0.01). Geometric Mean of Pairwise Ratios (GMPR)-normalized read counts were 
centered gene-wise to have a mean of 0 and standard deviation of 1. The “cluster” row 
annotations indicate the co-expression cluster identified by WGCNA. P04 clusters turquoise, 
purple and red, and P07 clusters turquoise and yellow were significantly enriched for bone 
marrow transcripts (hypergeometric test; FDR < 0.01). 
C) Graphs show the expression patterns for the co-expression clusters significantly enriched for 
bone marrow-enriched transcripts. Individual points are shown for each gene in the P04 (left) 
and P07 (right) co-expression clusters, and are colored according to the cluster IDs. Colored 
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lines indicate the mean expression of each cluster, and error bars represent a bootstrapped 
(B=1000) 98% CI of the mean. Black dashed lines indicate the white blood cell counts obtained 
from lab results measured on the same day.
 
Figure 6.  Relationship between temporal patterns of dynamically coexpressed plasma 
mRNA/lncRNA fragments and liver injury in patients undergoing allogeneic HSCT.
A,B) Heatmap of liver-enriched genes detected and found differentially-abundant by EBSeq-
HMM (FDR<0.01) in (A) P04 and (B) P07 samples.The “cluster” row annotations indicate the co-
expression clusters identified by WGCNA. P04 cluster, greenyellow, and P07 cluster, blue, were 
significantly enriched for liver-specific and enriched transcripts (hypergometric test; FDR < 0.01). 
C) Graph shows the expression for genes in the P04 co-expression cluster, greenyellow, along 
with AST and ALT lab values taken on the same day. 
D) Graph shows the expression of P07 co-expression cluster, blue, along with AST and ALT lab 
values. 
Data information: (C,D) Points represent the z-transformed log2 read counts for each of the 
genes in the cluster (P04 greenyellow: n=8; P07 blue: n=28). The black lines indicate the mean 
expression of each cluster and error bars represent a bootstrapped (B=1000) 98% CI of the 
means. Blue and red dashed lines represent lab values for AST and ALT liver enzymes, 
respectively. AST and ALT levels were centered to a mean of 0 and standard deviation of 1 for 
plotting. The actual lab values are shown for all elevated readings (AST > 30; ALT > 35).  
Expanded View Figure Legends
Figure EV1. Evaluation of extracellular microRNA recovery by phospho-RNA-seq and 
standard small RNA-seq. 
A) Boxplots summarize the total number of read alignments to human mature microRNAs. 
Overlaid points indicate the respective counts for  five control individuals, obtained from  three 
technical replicates. Boxes represent the mean +/- interquartile range (IQR), and whiskers 
represent 1st/3rd quartile 1.5 * IQR.  
B) Barplots indicate the number of mature microRNA genes detected (>=1 count)  in all five 
individuals with and without PNK treatment. 
C and D) Dotplots show the expression level (counts per million) of microRNAs that were 
detected only in  the (C) standard small RNA-seq or (D) phospho-RNA-seq protocols. Five 
points are shown for each miRNA, representing the miRNA abundance in each of the five 
controls. Blue dots indicate microRNAs removed from the current version of miRBase (v22) due 
to lack of functional evidence. Green dots indicate microRNAs overlapping transposable or 
repetitive element loci. Pink dots represent microRNAs not overlapping transposons or repeats 
and which are present in the current version of miRBase (miRBase 22). The number of 
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microRNAs in each of the categories are shown in parentheses in the legend of the respective 
plots.  
Expanded View Tables
Table EV1. Sequences of the equimolar synthetic pool.
Table EV2. mRNA and lncRNA fragments detected in plasma from healthy individuals using 
phospho-RNA-seq (PNK) and standard small RNA-seq (No.PNK) combined with a custom 
analysis pipeline.
Table EV3. Table of co-expression clustering results from dynamically-expressed genes in 
HSCT patient P04.
Table EV4. Table of co-expression clustering results from dynamically-expressed genes in 
HSCT patient P07.
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